Press Releases April 20, 2026 04:30 PM

JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering

JATT II Acquisition Corp closes $60 million IPO on NASDAQ to pursue healthcare and biotech acquisitions

By Nina Shah JATT
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
JATT

JATT II Acquisition Corp successfully closed its initial public offering, raising $60 million by issuing 6 million ordinary shares at $10 each, now trading on NASDAQ under ticker JATT. The blank check company plans to focus on mergers and acquisitions primarily in healthcare, biotechnology, and life sciences, with an emphasis on data-driven drug discovery approaches.

Key Points

  • JATT II Acquisition Corp raised $60 million in its IPO, with potential up to $69 million if over-allotment option is exercised.
  • The company is a Cayman Islands exempted blank check company focusing on mergers/acquisitions in healthcare, biotech, and life sciences sectors.
  • Target businesses include those leveraging machine learning, computational biology, and structure-based drug design for therapeutic development.

WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share on April 20, 2026. Total gross proceeds from the offering were $60,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The ordinary shares began trading on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “JATT” on April 17, 2026.

Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000 additional ordinary shares at the initial public offering price to cover over-allotments, if any.

A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 16, 2026. The public offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About JATT II Acquisition Corp

JATT II Acquisition Corp is a newly incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial business combination in any business or industry, the Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, the Company intends to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of the management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. The Company expects to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. The Company is sponsored by JATT Ventures II L.P. and is led by Dr. Someit Sidhu, Chief Executive Officer and Chairman of the Board, and Nicholas Fernandez, Chief Financial Officer. The Company’s Board of Directors also includes Verender S. Badial, Arjun Goyal, Jonathon Kluft and Christopher Staral, bringing extensive experience across biotechnology investing, company architecture, and public and private capital markets. Learn more at www.jattacquisition.com.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of JATT II Acquisition Corp, including those set forth in the Risk Factors section of JATT II Acquisition Corp’s registration statement and prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. JATT II Acquisition Corp undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts:

Nicholas Fernandez
Chief Financial Officer
153 Central Avenue
C/O 56
Westfield, NJ 07091
201-688-0364


Risks

  • No specific business combination target has been selected; the company may not complete any deal or generate returns for investors.
  • Reliance on successful identification and acquisition of companies in highly specialized and competitive biotech sectors.
  • Uncertainties inherent in forward-looking statements regarding use of proceeds and the success of future business combinations.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026